Viking’s VK2735 study showed dosing flexibility and meaningful weight loss, and the company plans to start Phase 3 by year-end, improving the program’s development outlook.
Viking’s VK2735 study showed strong preserved weight loss and a 22% placebo-adjusted drop at 33 weeks, and the company plans Phase 3 by year-end, so this readout meaningfully improves its program outlook.
Intuit dropped with other software names, marking further short-term pressure on the stock despite no company-specific news in this story.
Gen Digital extended a multi-session slide, which signals continued selling pressure in its software peer group.
Vicor raised its third-quarter revenue outlook and now guides sequential growth above 20%, which strengthens its near-term sales picture.
On Holding’s investor day set explicit sales and margin targets and authorized a $1 billion buyback, supporting its medium-term growth plan.
Monolithic Power Systems gained on renewed AI demand for power-delivery chips, which helps its revenue drivers even if it reflects sector momentum.
Follow Viking Therapeutics, Inc. (VKTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VKTX